Category | Biotech

Curis and Aurigene in immuno-oncology pact

Posted on 22 January 2015

Curis and Aurigene Discovery Technologies have entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets

Tags: ,

Agile Therapeutics bags $20 million in private placement

Posted on 21 January 2015

Agile Therapeutics has entered into a definitive stock purchase agreement with a group of institutional accredited investors, including both existing and new investors, for the private placement of approximately 3.4 million shares of common stock at $5.85 per share yielding expected gross proceeds of $20.0 million

Tags:

Celgene licenses AG-120 from Agios

Posted on 14 January 2015

Agios Pharmaceuticals announced that its collaboration partner Celgene has agreed that it will exercise its option to obtain an exclusive license outside the United States for AG-120

Tags: , , ,

Vedanta and Janssen partner for VE202

Posted on 14 January 2015

Vedanta Biosciences announced a license agreement with Janssen Biotech, for Vedanta’s lead microbiome pharmaceutical candidate (VE202)

Tags: , , ,

10X Genomics gains $55.5 million series B

Posted on 14 January 2015

10X Genomics has raised $55.5 Million in its Series B financing

Tags: ,

Cortendo snags $27.5 million financing

Posted on 14 January 2015

Cortendo has entered agreements with leading U.S. institutional specialist healthcare investors RA Capital Management, New Enterprise Associates (NEA) and Broadfin Capital

Tags:

BMS and Seattle evaluate Adcetris and Opdivo combination

Posted on 13 January 2015

Seattle Genetics and Bristol-Myers Squibb have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials

Tags: , ,

Medimmune licenses Omnis’ immuno-oncology program

Posted on 13 January 2015

MedImmune has entered into a licensing agreement with Omnis Pharmaceuticals

Tags: , ,

Amgen and Kite Pharma collaborate in CAR T cell immunotherapies

Posted on 06 January 2015

Amgen and Kite Pharma have entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies

Tags: , ,

Janssen and Isis in RNA-targeted therapeutics pact

Posted on 06 January 2015

Isis Pharmaceuticals has entered into a global collaboration with Janssen Biotech to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract

Tags: , , ,